Why Medicenna Therapeutics Corp. (MDNA) stock is gloomy today?
Shares of the Medicenna Therapeutics Corp. (MDNA) stock were declining in the current market following the announcement of clinical data from Phase 1/2 ABILITY Study. MDNA stock price saw a decline of 2.27% to drop at $2.15 a share at the time of this writing. The stock was also gloomy in the previous trade and […]
Why Medicenna Therapeutics Corp. (MDNA) stock is gloomy today? Read More »